Loading...
Market
Will AstraZeneca pay the full $1.9 billion in milestone payments for CSPC's Lp(a) drug by 2030?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Financial disclosures or official press releases from AstraZeneca or CSPC Pharmaceutical Group Ltd
Story
AstraZeneca to Pay Up to $2 Billion for CSPC's AI-Developed Lp(a) Cardiovascular Drug
Oct 7, 2024, 09:00 AM
AstraZeneca has entered into an exclusive licensing agreement with Hong Kong-listed CSPC Pharmaceutical Group Ltd, agreeing to pay up to $2 billion to enhance its cardiovascular pipeline. The deal includes a $100 million upfront payment and potential milestone payments totaling up to $1.9 billion. The licensed therapy is a preclinical small molecule targeting lipoprotein(a), or Lp(a), developed using CSPC Pharma's AI platform. This lipid-lowering drug aims to address cardiovascular diseases by reducing Lp(a) levels. The agreement underscores AstraZeneca's commitment to leveraging innovative technologies from Chinese biotech firms to strengthen its position in the cardiovascular market.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $100 million • 25%
$100 million to $299 million • 25%
$300 million to $499 million • 25%
$500 million or more • 25%
Less than $100 million • 25%
$100 million to $300 million • 25%
$300 million to $500 million • 25%
More than $500 million • 25%
Yes • 50%
No • 50%
